Forschung

Direkt zum Inhalt | Direkt zur Navigation

Benutzerspezifische Werkzeuge

Sektionen
Humanes Immundefizienz Virus
Sie sind hier: Startseite / Forschung / Humanes Immundefizienz Virus

Humanes Immundefizienz Virus

Ausgewählte Publikationen zum Thema Humanes Immundefizienz Virus - HIV (chronologisch sortiert)

 


Noguera-Julian M, Cozzi-Lepri A, Di Giallonardo F, Schuurman R, Daumer M, Aitken S, Ceccherini-Silberstein F, D'Arminio Monforte A, Geretti AM, Booth CL, Kaiser R, Michalik C, Jansen K, Masquelier B, Bellecave P, Kouyos RD, Castro E, Furrer H, Schultze A, Gunthard HF, Brun-Vezinet F, Metzner KJ, Paredes R. (2015). Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants. Clin Microbiol Infect. www.ncbi.nlm.nih.gov/pubmed/26482266

Doyle T, Dunn DT, Ceccherini-Silberstein F, De Mendoza C, Garcia F, Smit E, Fearnhill E, Marcelin AG, Martinez-Picado J, Kaiser R, Geretti AM. (2015). Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades. J Antimicrob Chemother. 70(11): 3080-3086. www.ncbi.nlm.nih.gov/pubmed/26311843

Cozzi-Lepri A, Noguera-Julian M, Di Giallonardo F, Schuurman R, Daumer M, Aitken S, Ceccherini-Silberstein F, D'Arminio Monforte A, Geretti AM, Booth CL, Kaiser R, Michalik C, Jansen K, Masquelier B, Bellecave P, Kouyos RD, Castro E, Furrer H, Schultze A, Gunthard HF, Brun-Vezinet F, Paredes R, Metzner KJ. (2015). Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing. J Antimicrob Chemother. 70(3): 930-940. www.ncbi.nlm.nih.gov/pubmed/25336166

Charpentier C, Camacho R, Ruelle J, Eberle J, Gurtler L, Pironti A, Sturmer M, Brun-Vezinet F, Kaiser R, Descamps D, Obermeier M. (2015). HIV-2EU-Supporting Standardized HIV-2 Drug-Resistance Interpretation in Europe: An Update. Clin Infect Dis. 61(8): 1346-1347. www.ncbi.nlm.nih.gov/pubmed/26187019


Schweitzer F, Mikkola V, Timmen-Wego M, Jensen B, Fatkenheuer G, Kaiser R. (2014). Longitudinal comparison of HIV-1 plasma viral load and cellular proviral load. J Int AIDS Soc. 17(4 Suppl 3): 19669. www.ncbi.nlm.nih.gov/pubmed/25397419

Schulter E, Kaiser R, Zazzi M, Sonnerborg A, Camacho R, Verheyen J. (2014). Time on drug analysis based on real life data. J Int AIDS Soc. 17(4 Suppl 3): 19790. www.ncbi.nlm.nih.gov/pubmed/25397534

Pironti A, Pfeifer N, Kaiser R, Walter H, Lengauer T. (2014). Improved therapy-success prediction with GSS estimated from clinical HIV-1 sequences. J Int AIDS Soc. 17(4 Suppl 3): 19743. www.ncbi.nlm.nih.gov/pubmed/25397488

Neogi U, Rao SD, Bontell I, Verheyen J, Rao VR, Gore SC, Soni N, Shet A, Schulter E, Ekstrand ML, Wondwossen A, Kaiser R, Madhusudhan MS, Prasad VR, Sonnerborg A. (2014). Novel tetra-peptide insertion in Gag-p6 ALIX-binding motif in HIV-1 subtype C associated with protease inhibitor failure in Indian patients. AIDS. 28(15): 2319-2322. www.ncbi.nlm.nih.gov/pubmed/25102091

Lengauer T, Pfeifer N, Kaiser R. (2014). Personalized HIV therapy to control drug resistance. Drug Discov Today Technol. 11:57-64. www.ncbi.nlm.nih.gov/pubmed/24847654

Kordelas L, Verheyen J, Beelen DW, Horn PA, Heinold A, Kaiser R, Trenschel R, Schadendorf D, Dittmer U, Esser S. (2014). Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation. N Engl J Med. 371(9): 880-882. www.ncbi.nlm.nih.gov/pubmed/25162903


Libin P, Beheydt G, Deforche K, Imbrechts S, Ferreira F, Van Laethem K, Theys K, Carvalho AP, Cavaco-Silva J, Lapadula G, Torti C, Assel M, Wesner S, Snoeck J, Ruelle J, De Bel A, Lacor P, De Munter P, Van Wijngaerden E, Zazzi M, Kaiser R, Ayouba A, Peeters M, de Oliveira T, Alcantara LC, Grossman Z, Sloot P, Otelea D, Paraschiv S, Boucher C, Camacho RJ, Vandamme AM. (2013). RegaDB: community-driven data management and analysis for infectious diseases. Bioinformatics. 29(11): 1477-1480. www.ncbi.nlm.nih.gov/pubmed/23645815

Horwitz JA, Halper-Stromberg A, Mouquet H, Gitlin AD, Tretiakova A, Eisenreich TR, Malbec M, Gravemann S, Billerbeck E, Dorner M, Buning H, Schwartz O, Knops E, Kaiser R, Seaman MS, Wilson JM, Rice CM, Ploss A, Bjorkman PJ, Klein F, Nussenzweig MC. (2013). HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc Natl Acad Sci U S A. 110(41): 16538-16543. www.ncbi.nlm.nih.gov/pubmed/24043801

De Luca A, Dunn D, Zazzi M, Camacho R, Torti C, Fanti I, Kaiser R, Sonnerborg A, Codoner FM, Van Laethem K, Vandamme AM, Bansi L, Ghisetti V, van de Vijver DA, Asboe D, Prosperi MC, Di Giambenedetto S. (2013). Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. J Infect Dis. 207(8): 1216-1220. www.ncbi.nlm.nih.gov/pubmed/23315324

Charpentier C, Camacho R, Ruelle J, Kaiser R, Eberle J, Gurtler L, Pironti A, Sturmer M, Brun-Vezinet F, Descamps D, Obermeier M. (2013). HIV-2EU: supporting standardized HIV-2 drug resistance interpretation in Europe. Clin Infect Dis. 56(11): 1654-1658. www.ncbi.nlm.nih.gov/pubmed/23429380

Bozek K, Lengauer T, Sierra S, Kaiser R, Domingues FS. (2013). Analysis of physicochemical and structural properties determining HIV-1 coreceptor usage. PLoS Comput Biol. 9(3): e1002977. www.ncbi.nlm.nih.gov/pubmed/23555214


Kaiser R, Wensing AM. (2012). HIV co-receptor tropism: old target for new therapeutic strategies. Curr Opin HIV AIDS. 7(5): 429-431. www.ncbi.nlm.nih.gov/pubmed/22789988

DAIG (2012) Deutsch-Österreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion.

Bozek K, Eckhardt M, Sierra S, Anders M, Kaiser R, Krausslich HG, Muller B, Lengauer T. (2012). An expanded model of HIV cell entry phenotype based on multi-parameter single-cell data. Retrovirology. 9: 60. www.ncbi.nlm.nih.gov/pubmed/22830600


Vandekerckhove LP, Wensing AM, Kaiser R, Brun-Vezinet F, Clotet B, De Luca A, Dressler S, Garcia F, Geretti AM, Klimkait T, Korn K, Masquelier B, Perno CF, Schapiro JM, Soriano V, Sonnerborg A, Vandamme AM, Verhofstede C, Walter H, Zazzi M, Boucher CA. (2011). European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis. 11(5): 394-407. www.ncbi.nlm.nih.gov/pubmed/21429803

Prosperi MC, Mackie N, Di Giambenedetto S, Zazzi M, Camacho R, Fanti I, Torti C, Sonnerborg A, Kaiser R, Codoner FM, Van Laethem K, Bansi L, van de Vijver DA, Geretti AM, De Luca A. (2011). Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. J Antimicrob Chemother. 66(8): 1886-1896. www.ncbi.nlm.nih.gov/pubmed/21624929


Verheyen J, Verhofstede C, Knops E, Vandekerckhove L, Fun A, Brunen D, Dauwe K, Wensing AM, Pfister H, Kaiser R, Nijhuis M. (2010). High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates. AIDS. 24(5): 669-673. www.ncbi.nlm.nih.gov/pubmed/19926962

Thielen A, Sichtig N, Kaiser R, Lam J, Harrigan PR, Lengauer T. (2010). Improved prediction of HIV-1 coreceptor usage with sequence information from the second hypervariable loop of gp120. J Infect Dis. 202(9): 1435-1443. www.ncbi.nlm.nih.gov/pubmed/20874088

Knops E, Kemper I, Schulter E, Pfister H, Kaiser R, Verheyen J. (2010). The evolution of protease mutation 76V is associated with protease mutation 46I and gag mutation 431V. AIDS. 24(5): 779-781. www.ncbi.nlm.nih.gov/pubmed/20139751

Knops E, Daumer M, Awerkiew S, Kartashev V, Schulter E, Kutsev S, Brakier-Gingras L, Kaiser R, Pfister H, Verheyen J. (2010). Evolution of protease inhibitor resistance in the gag and pol genes of HIV subtype G isolates. J Antimicrob Chemother. 65(7): 1472-1476. www.ncbi.nlm.nih.gov/pubmed/20430786


Gronewold, T. M., A. Baumgartner, J. Hierer, S. Sierra, M. Blind, F. Schafer, J. Blumer, T. Tillmann, A. Kiwitz, R. Kaiser, M. Zabe-Kuhn, E. Quandt and M. Famulok (2009). "Kinetic Binding Analysis of Aptamers Targeting HIV-1 Proteins by a Combination of a Microbalance Array and Mass Spectrometry (MAMS)." J Proteome Res. 67

Sichtig, N., S. Sierra, R. Kaiser, M. Däumer, S. Reuter, E. Schülter, A. Altmann, G. Fatkenheuer, U. Dittmer, H. Pfister and S. Esser (2009). "Evolution of raltegravir resistance during therapy." J Antimicrob Chemother 64(1): 25-32. 68

Altmann, A., T. Sing, H. Vermeiren, B. Winters, E. Van Craenenbroeck, K. Van der Borght, S. Y. Rhee, R. W. Shafer, E. Schülter, R. Kaiser, Y. Peres, A. Sonnerborg, W. J. Fessel, F. Incardona, M. Zazzi, L. Bacheler, H. Van Vlijmen and T. Lengauer (2009). "Advantages of predicted phenotypes and statistical learning models in inferring virological response to antiretroviral therapy from HIV genotype." Antivir Ther 14(2): 273-283. 69

Balduin, M., M. Oette, M. P. Daumer, D. Hoffmann, H. J. Pfister and R. Kaiser (2009). "Prevalence of minor variants of HIV strains at reverse transcriptase position 103 in therapy-naive patients and their impact on the virological failure." J Clin Virol 45(1): 34-38. 70

Altmann, A., M. Däumer, N. Beerenwinkel, Y. Peres, E. Schülter, J. Buch, S. Y. Rhee, A. Sonnerborg, W. J. Fessel, R. W. Shafer, M. Zazzi, R. Kaiser and T. Lengauer (2009). "Predicting the response to combination antiretroviral therapy: retrospective validation of geno2pheno-THEO on a large clinical database." J Infect Dis 199(7): 999-1006.

Verheyen, J., E. Knops, B. Kupfer, O. Hamouda, S. Somogyi, U. Schuldenzucker, D. Hoffmann, R. Kaiser, H. Pfister and C. Kucherer (2009). "Prevalence of C-terminal gag cleavage site mutations in HIV from therapy-naive patients." J Infect 58(1): 61-67.

Bozek, K., A. Thielen, S. Sierra, R. Kaiser and T. Lengauer (2009). "V3 loop sequence space analysis suggests different evolutionary patterns of CCR5- and CXCR4-tropic HIV." PLoS One 4(10): e7387. http://www.ncbi.nlm.nih.gov/pubmed/19816596

Verheyen, J., M. Balduin, R. Kaiser and H. Pfister (2009). "Seasonal influenza virus species in patient swab samples analyzed for the presence of the pandemic (H1N1) 2009 influenza virus." J Clin Microbiol 47(12): 4187-4188. http://www.ncbi.nlm.nih.gov/pubmed/19794039

Sierra, S., T. Lengauer and R. Kaiser (2009). "[Resistance screening]." MMW Fortschr Med 151(18): 72, 74-75. http://www.ncbi.nlm.nih.gov/pubmed/19769083

Kaiser, R. (2009). "[Update tick-borne encephalitis]." MMW Fortschr Med 151(11): 38-39. http://www.ncbi.nlm.nih.gov/pubmed/19469203


Sierra, S., R. Kaiser, A. Thielen, O. Sander and T. Lengauer (2008). Genotypic Analysis of HIV Co-Receptor Usage. Entry Inhibitoren. H. Jäger. Heidelberg, Springer Medizin: 31-40.66

Paar, C., C. Palmetshofer, K. Flieger, M. Geit, R. Kaiser, H. Stekel and J. Berg (2008). "Genotypic antiretroviral resistance testing for human immunodeficiency virus type 1 integrase inhibitors by use of the TruGene sequencing system." J Clin Microbiol 46(12): 4087-4090. 73

Altmann, A., M. Rosen-Zvi, M. Prosperi, E. Aharoni, H. Neuvirth, E. Schulter, J. Buch, D. Struck, Y. Peres, F. Incardona, A. Sonnerborg, R. Kaiser, M. Zazzi and T. Lengauer (2008). "Comparison of classifier fusion methods for predicting response to anti HIV-1 therapy." PLoS One 3(10): e3470. 74

Rosen-Zvi, M., A. Altmann, M. Prosperi, E. Aharoni, H. Neuvirth, A. Sonnerborg, E. Schülter, D. Struck, Y. Peres, F. Incardona, R. Kaiser, M. Zazzi and T. Lengauer (2008). "Selecting anti-HIV therapies based on a variety of genomic and clinical factors." Bioinformatics 24(13): i399-406. 75